Clinical Trial Update: Pentavalent DTaP-Hep B-IPV [Phase 2]

View source ↗

Summary

Phase 2 trial of the pentavalent DTaP-Hep B-IPV vaccine has completed, evaluating protection against diphtheria, hepatitis B, poliomyelitis, pertussis, and teta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• Pentavalent DTaP-Hep B-IPV

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Diphtheria, Hepatitis B | Phase 2 | Status: COMPLETED